TE
Trails Edge Capital Partners, LP disclosed a 5.1% stake in CTNM
Trails Edge Capital Partners, LP reported owning 5.1% of Contineum Therapeutics, Inc. (CTNM) (1,679,443 shares) in a Schedule 13G filed Oct 22, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 22, 2026
- Source
- Schedule 13G